Driving API success: key considerations for NCE (New Chemical Entities) development and manufacturing
Unlock API (Active Pharmaceutical Ingredient) success for your NCEs (New Chemical Entities). Discover key development insights, case studies on potent APIs and critical intermediates. Join us to learn more about Seqens’ collaborative model to accelerate and de-risk your path from lab to market.
Three Takeaways
- Critical aspects to consider during API development and manufacturing: from laboratory to commercial scale.
- Case studies showing how key technologies allow to overcome development bottlenecks.
- Seqens’ collaborative model to accelerate and de-risk NCE development for its partners.
Speakers
- Gaurab Sengupta, Commercial Director, Seqens.
- Ronan Rocle, Sales & Business Development Manager CDMO, Seqens.
- Aamar Khan, Sales & Business Development Manager CDMO, Seqens.
About Seqens
Seqens, with over 30 years' experience, is a global leader in the pharmaceutical industry, with a strong focus on the development and manufacture of APIs, intermediates and polymers. Their R&D facilities in Europe and in the US together with their network of 8 manufacturing sites (GMP and nonGMP) enable them to offer a wide range of solutions to innovative pharmaceutical companies. Seqens supports its customers from early-stage development to commercial production, offering tailored solutions for complex molecules.